AKAP 14 Activators
AKAP14 activators are a diverse group of chemical compounds that target various points in the cAMP/PKA signaling cascade, a pathway critical for numerous cellular processes and directly associated with the scaffolding capabilities of AKAP14. Forskolin, Isoproterenol, PGE2, and other adenylyl cyclase activators function by increasing intracellular cAMP, which binds to the regulatory subunits of PKA, leading to the release and activation of the catalytic subunits. Once activated, PKA phosphorylates a variety of substrates, and AKAP14 enhances this process by anchoring PKA to specific subcellular locations where these phosphorylation events can occur efficiently.
On the other end of the regulatory spectrum, compounds such as H-89, A-kinase Inhibiting Peptide, and Okadaic Acid interact with the inhibition and dephosphorylation aspects of the PKA pathway. H-89 and AIP serve as PKA inhibitors, leading to a compensatory upregulation of AKAP14 activity to concentrate PKA where it is needed most. Okadaic Acid prevents the dephosphorylation of PKA substrates, thereby sustaining PKA activity and, as a result, promoting AKAP14's role in organizing PKA signaling. Cilostamide, Rolipram, and IBMX inhibit phosphodiesterases leading to elevated cAMP and enhanced PKA activity, which in turn augments AKAP14's scaffolding function. The use of cAMP analogs like Sp-8-Br-cAMPS, 8-CPT-cAMP, and Dibutyryl cAMP provides a direct means of PKA activation, thereby reinforcing the role of AKAP14 in PKA signaling pathways.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Forskolin | 66575-29-9 | sc-3562 sc-3562A sc-3562B sc-3562C sc-3562D | 5 mg 50 mg 1 g 2 g 5 g | $78.00 $153.00 $740.00 $1413.00 $2091.00 | 73 | |
Adenylyl cyclase activator that increases cAMP levels in cells. AKAP14 anchors protein kinase A (PKA), which is activated by cAMP. Elevated cAMP levels lead to PKA activation, and because AKAP14 binds PKA, this enhances AKAP14's scaffolding function. | ||||||
H-89 dihydrochloride | 130964-39-5 | sc-3537 sc-3537A | 1 mg 10 mg | $94.00 $186.00 | 71 | |
PKA inhibitor that indirectly enhances AKAP14's role in compensating for inhibited PKA activity by increasing the recruitment of PKA to AKAP14 complexes to maintain necessary PKA signaling functions. | ||||||
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Non-specific inhibitor of phosphodiesterases, which leads to increased cAMP levels. This would result in enhanced PKA activity and thereby increase AKAP14's function in scaffolding PKA to specific subcellular compartments. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Serine/threonine phosphatase inhibitor that can prevent the dephosphorylation of PKA substrates, leading to sustained PKA activity and thus potentially enhancing the role of AKAP14 in organizing PKA signaling. | ||||||
Isoproterenol Hydrochloride | 51-30-9 | sc-202188 sc-202188A | 100 mg 500 mg | $28.00 $38.00 | 5 | |
A beta-adrenergic agonist that increases intracellular cAMP levels, leading to the activation of PKA and the subsequent enhancement of AKAP14-mediated PKA signaling pathways. | ||||||
Astragaloside IV | 84687-43-4 | sc-257103 | 20 mg | $57.00 | 1 | |
Specific inhibitor of PKA that can lead to an upregulation of AKAP14's role in localizing PKA to certain areas within the cell to maintain adequate signaling despite the inhibition of PKA activity. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Prostaglandin E2 activates G protein-coupled receptors that can increase cAMP levels, enhancing PKA activity and consequently AKAP14's scaffolding function by increasing the association between PKA and AKAP14. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Selective inhibitor of phosphodiesterase 4 (PDE4), which raises cAMP levels, enhancing PKA activation and thereby potentially increasing AKAP14-mediated targeting of PKA to specific cellular locations. | ||||||
Cilostamide (OPC 3689) | 68550-75-4 | sc-201180 sc-201180A | 5 mg 25 mg | $92.00 $357.00 | 16 | |
Inhibitor of phosphodiesterase 3 (PDE3) that increases cAMP levels, thereby enhancing PKA activity and potentially AKAP14's role in directing PKA signaling pathways. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cell-permeable cAMP analog that activates PKA. As PKA activity is enhanced, so is the role of AKAP14 in anchoring PKA to specific subcellular domains. | ||||||